<![CDATA[Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer]]>

Advertisement News|Articles|May 8, 2026 Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer Author(s)Ashling Wahner Fact checked by: Riley Kandel Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer. Advertisement The combination of sacituzumab govitecan-hziy (Trodelvy) and trastuzumab (Herceptin) elicited an overall response rate (ORR) of 3.7% (95% CI, 0.1%-19%) in patients with HER2-positive metastatic breast cancer who had previously received fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu), failing to meet the primary end point of the phase 2 SATEEN trial (NCT05113251) presented at the 2026 ESMO Breast Cancer Congress.1One confirmed partial response was observed among 27 evaluable patients, and the clinical benefit rate among these patients for 18 weeks or longer was 14.8% (95% CI, 4%-33%). Due to these results, the trial was stopped for futility after the first stage of the Simon’s 2-stage design.“This constitutes the first prospective data for sacituzumab govitecan plus trastuzumab in HER2-positive disease,” Paolo Tarantino, MD, PhD, a clinical fellow at Dana-Farber Cancer Institute in Boston, Massachusetts, stated in a presentation of the data.What was the rationale for investigating sacituzumab govitecan after T-DXd in patients with HER2-positive metastatic breast cancer?Although T-DXd is a standard therapy for HER2-positive metastatic breast cancer, Tarantino explained that no prospective data currently exist to guide treatment selection following progression on the agent. He also noted that research has shown that HER2 is often downregulated following T-DXd treatment, whereas TROP2 is highly expressed in HER2-positive breast cancer, supporting the potential of TROP2-targeted therapy in this setting.Sacituzumab govitecan is a TROP2-directed antibody-drug conjugate (ADC) featuring a topoisomerase-1 (TOPO1) inhibitor payload that is FDA approved for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least 2 prior systemic therapies, with at least 1 of them for metastatic disease; and for the treatment of patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have previously received endocrine therapy and at least 2 additional systemic therapies in the metastatic setting.2 Although this ADC has generated survival benefits in these patient populations, it had not been previously tested in the HER2-positive setting or specifically after T-DXd, Tarantino contextualized.1What was the design of the SATEEN trial?SATEEN was a single-arm, investigator-initiated, multicenter trial. Using a Simon’s 2-stage design, the trial required a minimum of 3 responders among the first 27 patients in stage 1 to proceed to stage 2. The trial was powered to distinguish an ORR of 25% from a null ORR of 10%.Patients received sacituzumab govitecan at 10 mg/kg intravenously on days 1 and 8 of 21-day cycles in combination with trastuzumab every 3 weeks (administered intravenously or subcutaneously).What were the baseline characteristics of the SATEEN trial patient population?The 27 patients enrolled in the first stage had a median age of 55 years. The population was heavily pretreated, with a median of 5 prior anti-HER2 lines for metastatic disease (range, 1-17). All patients had previously received trastuzumab and pertuzumab (Perjeta), 70% of patients had received ado-trastuzumab emtansine (T-DM1; Kadcyla), and 74% of patients had received a HER2-directed TKI like tucatinib (Tukysa), neratinib (Nerlynx), or lapatinib (Tykerb).Regarding prior T-DXd treatment, 81% of patients had discontinued the agent due to disease progression, whereas 15% of patients had discontinued the agent without progression. The median time spent on prior T-DXd was 12 months (range, 2-35). At enrollment, 70% of patients had visceral metastases, and 33% of patients had brain metastases (18% active and 15% stable).What survival outcomes were observed in the SATEEN trial?The median progression-free survival for the total population was 2.3 months (95% CI, 2.0-3.5). The median overall survival was 9.2 months (95% CI, 7.6-not reached).What was the safety profile of sacituzumab govitecan plus trastuzumab in T-DXd–pretreated HER2-positive metastatic breast cancer?Treatment-related adverse effects (TRAEs) of grade 2 or higher occurred in 85% of patients. Grade 3 TRAEs were reported in 48% of patients, and grade 4 TRAEs occurred in 26% of patients. Dose modifications due to AEs were required for 33% of patients in the population.The most common grade 2 or higher TRAEs included:Anemia (grade ≥ 2, 59%; grade 3, 26%; grade 4, 0%)Neutropenia (59%; 30%; 30%)Diarrhea (30%; 19%; 0%)Fatigue (26%; 4%; 0%)Notably, there was 1 grade 5 TRAE involving neutropenic sepsis with multi-organ failure. Following this event, the study investigators implemented mandatory growth factor support after day 8 of each cycle.“Safety was consistent with prior sacituzumab govitecan trials, although these data do emphasize the importance of growth factor support, especially in heavily pretreated patients receiving sacituzumab govitecan,” Tarantino concluded. “Biomarker analyses are ongoing to understand the reasons why tumors become resistant to TOPO1-directed ADCs to guide sequential ADC treatment and optimize treatment beyond ADCs.”Disclosures: Tarantino reported performing consultant/advisory roles for AstraZeneca, Daiichi Sankyo, Gilead, Eli Lilly, Menarini/Stemline, Novartis, Roche/Genentech, and Sanofi; performing speaking roles for AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, and Roche/Genentech; and receiving institutional research funding from AstraZeneca and Ignite Proteomics.ReferencesTarantino P, Yu L, Faggen M, et al. Efficacy and safety of sacituzumab govitecan (SG) plus trastuzumab in patients with HER2+ metastatic breast cancer after prior trastuzumab deruxtecan (T-DXd): results from the phase II SATEEN trial. Presented at: 2025 ESMO Breast Cancer Congress. May 6-8, 2026; Berlin, Germany. Abstract LBA4.Trodelvy. Prescribing information. Gilead; March 2025. Accessed May 8, 2026. https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementCapivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerByAshling Wahner May 8th 2026FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma ByAshling Wahner May 8th 2026UT MD Anderson Shares Latest Research BreakthroughsByMD Anderson Cancer CenterMay 8th 2026Giants of Cancer Care Announces the 14th Annual Class of Inductees ByOncLiveMay 8th 2026OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer UpdatesByOncLive StaffMay 8th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer2FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma 3Mentorship Is Key to Advance the Next Generation of Oncology Researchers4Dr Mauro on the Significance of Alternative TKI Formulations in CML5First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC